CME Sessions at EANM’07

EANM’07 – CME Session XII

October 17, 2007, 08:00 – 09:30
Neuroendocrine Tumours

Moderator: E. Bombardieri (Milano)
Co-Moderator: R. P. Baum (Bad Berka)

H. Maecke (Basel):
Peptides and radionuclides for imaging and therapy of NET: current status and future developments
R. P. Baum (Bad Berka):
Diagnosis, staging and restaging of NETin patients undergoing peptide receptor radionuclide therapy using receptor PET/CT – state of the art
D. J. Kwekkeboom (Rotterdam):
PRRT of neuroendocrine tumours using Lu- 177 DOTA-TATE – long-term experience and future perspectives

Educational objectives:

  1. overview the radiopharmaceuticals today available for targeting neuroendocrine tumours and discuss the development of the new experimental molecules suitable for diagnosis and therap
  2. describe the strength of receptor PET/CT in diagnosis, staging and restaging of neuroendocrine tumours
  3. discuss what is the present role of In-111 pentetreotide imaging in comparison with positron-emitting radiofarmaceuticals in those facilities where a choice is possible;
  4. develop a strategy in order to adopt a radioreceptor radionuclide therapy guided by pre-treatment imaging and dosimetry based on the unique radiopharmaceutical (Lu-177 DOTA-TATE )


This session has been designed for nuclear medicine physicians, oncologists and endocrinologists involved or interested in the diagnosis and treatment of neuroendocrine tumours. The first presentation will provide a general overview on the radiopharmaceuticals currently used to visualize neuroendocrine tumours, focusing the attention to the development of new molecules suitable for targeting neuroendocrine cells and useful also for therapy. The imaging of neuroendocrine tumours can be obtained both by scintigraphy with gamma emitting radiopharmaceuticals and by positron emission tomography (PET). This is the topic of the second lecture that will discuss the role of PET with new somatostatin analogues ( DOTA-NOC or DOTA-TOC) radiolabelled with positron-emitting radioisotopes such as Gallium-68. The clinical data suggest that these radiotracers are superior to the existing radiolabelled traditional somatostatin analogues and these new approaches seem to bring a great improvement in managing neuroendocrine tumours. The third lecture will stress the clinical use of the radioreceptor therapy guided by a pre-treatment imaging and dosimetry by using the same radiopharmaceuitical, beta and gamma emitter, namely Lu-177 DOTA-TATE. Other issues that will be considered in this course are the position of these new procedures in the diagnostic and therapeutic strategy for neuroendocrine tumours and the cost/benefit balance.

Key Words:

neuroendocrine tumours, radioreceptor radionuclide imaging, radioreceptor, radionuclide therapy, radiolabelled somatostatin, radiopharmaceuticals

Back to top